VERTEX PHARMACEUTICALS INC / MA reported revenue of $3.33B for the period ended 2026-06-30, +12.5% year on year. Net income was $1.10B, a 33.0% net margin on a 85.3% gross margin. The largest revenue line is TRIKAFTAKAFTRIO at 75% of the total. Free cash flow for the period was $1.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $3.33B | +12.5% |
| Gross profit | $2.84B | — |
| Operating income | $1.25B | — |
| Net income | $1.10B | +6.5% |
| Gross margin | 85.3% | Net margin 33.0% |
| Revenue Q/Q | +11.6% | — |
| Segment | Revenue | Share |
|---|---|---|
| TRIKAFTAKAFTRIO | $2.50B | 74.9% |
| ALYFTREK | $0.57B | 17.2% |
| Manufactured Product Other | $0.14B | 4.1% |
| CASGEVY | $0.08B | 2.3% |
| JOURNAVX | $0.05B | 1.5% |
| Collaborativeand Royalty | $0.00B | 0.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | $0.49B | 14.7% |
| SG&A | $0.58B | 17.5% |
| Tax & other | $0.15B | 4.4% |
| Item | Amount |
|---|---|
| Total assets | $27.42B |
| Total liabilities | $7.18B |
| Shareholders' equity | $20.25B |
| Equity / assets | 73.8% |
| Operating cash flow | $1.13B |
| Capital expenditure | $0.11B |
| Free cash flow | $1.01B |
| Cash conversion (OCF / net income) | 102% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
VRT ・ VTRS ・ VICI ・ V ・ VST ・ VMC ・ WRB ・ GWW ・ WAB ・ WMT ・ DIS ・ WBD
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies